DRUG TESTING - OTHER & Cannabis studies completed
DRUG TESTING - OTHER & Cannabis studies completed
Science and Research
2011 - Study ~ Versatile new ion source for the analysis of materials in open air under ambient conditions.
2010 - Study ~ Drugs of abuse in airborne particulates in urban environments.
2008 - Study - Excretion of Δ9-tetrahydrocannabinol in sweat
2008 - Study - Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse
2008 - News ~ CSI: fingerprinting and drug detection in one2007 - Study ~ Prevalence of gestational exposure to cannabis in a Mediterranean city by meconium analysis.
2006 - Study ~ Determination of the prevalence of drug misuse by meconium analysis
2004 - Study ~ Usefulness of Sweat Testing for the Detection of Cannabis Smoke
2003 - Study ~ Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse
2000 - News ~ Wiping Up the Evidence
1999 - Study ~ Nail Analysis for Drugs of Abuse: Extraction and Determination of Cannabis in Fingernails by Ria and Gc-ms.
also see
DRUG INTERACTIONS also see INTERACTIONS WITH OTHER DRUGS
DRUG TESTING
DRUG TESTING - BLOOD
DRUG TESTING - HAIR
DRUG TESTING - ORAL
DRUG TESTING - OTHER
DRUG TESTING - URINE
Comparison of meconium and neonatal hair analysis for detection of gestational exposure to drugs of abuse
Arch Dis Child Fetal Neonatal Ed. 2003 March; 88(2): F98–F100. doi: 10.1136/fn.88.2.F98. | PMCID: PMC1721515 |

- Jekel JF, Allen DF, Podlewski H, Clarke N, Dean-Patterson S, Cartwright P. Epidemic free-base cocaine abuse. Case study from the Bahamas. Lancet. 1986 Mar 1;1(8479):459–462. [PubMed]
- Volpe JJ. Effect of cocaine use on the fetus. N Engl J Med. 1992 Aug 6;327(6):399–407. [PubMed]
- Gillogley KM, Evans AT, Hansen RL, Samuels SJ, Batra KK. The perinatal impact of cocaine, amphetamine, and opiate use detected by universal intrapartum screening. Am J Obstet Gynecol. 1990 Nov;163(5 Pt 1):1535–1542. [PubMed]
- Chasnoff IJ, Griffith DR. Cocaine: clinical studies of pregnancy and the newborn. Ann N Y Acad Sci. 1989;562:260–266. [PubMed]
- Addis A, Moretti ME, Ahmed Syed F, Einarson TR, Koren G. Fetal effects of cocaine: an updated meta-analysis. Reprod Toxicol. 2001 Jul–Aug;15(4):341–369. [PubMed]
- Chasnoff IJ, Bussey ME, Savich R, Stack CM. Perinatal cerebral infarction and maternal cocaine use. J Pediatr. 1986 Mar;108(3):456–459. [PubMed]
- Lopez SL, Taeusch HW, Findlay RD, Walther FJ. Time of onset of necrotizing enterocolitis in newborn infants with known prenatal cocaine exposure. Clin Pediatr (Phila) 1995 Aug;34(8):424–429. [PubMed]
- Frank DA, Augustyn M, Knight WG, Pell T, Zuckerman B. Growth, development, and behavior in early childhood following prenatal cocaine exposure: a systematic review. JAMA. 2001 Mar 28;285(12):1613–1625. [PMC free article] [PubMed]
- Frank Deborah A, Augustyn Marilyn, Knight Wanda Grant, Pell Tripler, Zuckerman Barry. Growth, Development, and Behavior in Early Childhood Following Prenatal Cocaine Exposure: A Systematic Review. JAMA. 2008 May 2;285(12):1613–1625. [PMC free article] [PubMed]
- Franck L, Vilardi J. Assessment and management of opioid withdrawal in ill neonates. Neonatal Netw. 1995 Mar;14(2):39–48. [PubMed]
- Dixon SD. Effects of transplacental exposure to cocaine and methamphetamine on the neonate. West J Med. 1989 Apr;150(4):436–442. [PMC free article] [PubMed]
- Dixon SD. Effects of transplacental exposure to cocaine and methamphetamine on the neonate. West J Med. 1989 Apr;150(4):436–442. [PMC free article] [PubMed]
- Birchfield M, Scully J, Handler A. Perinatal screening for illicit drugs: policies in hospitals in a large metropolitan area. J Perinatol. 1995 May–Jun;15(3):208–214. [PubMed]
- Forman R, Klein J, Meta D, Barks J, Greenwald M, Koren G. Maternal and neonatal characteristics following exposure to cocaine in Toronto. Reprod Toxicol. 1993 Nov–Dec;7(6):619–622. [PubMed]
- Ostrea EM, Jr, Knapp DK, Tannenbaum L, Ostrea AR, Romero A, Salari V, Ager J. Estimates of illicit drug use during pregnancy by maternal interview, hair analysis, and meconium analysis. J Pediatr. 2001 Mar;138(3):344–348. [PubMed]
- Cirimele V, Kintz P, Mangin P. Testing human hair for cannabis. Forensic Sci Int. 1995 Jan 5;70(1-3):175–182. [PubMed]
- Graham K, Koren G, Klein J, Schneiderman J, Greenwald M. Determination of gestational cocaine exposure by hair analysis. JAMA. 1989 Dec 15;262(23):3328–3330. [PubMed]
- Klein J, Karaskov T, Koren G. Clinical applications of hair testing for drugs of abuse--the Canadian experience. Forensic Sci Int. 2000 Jan 10;107(1-3):281–288. [PubMed]
- Koren G, Klein J, Forman R, Graham K. Hair analysis of cocaine: differentiation between systemic exposure and external contamination. J Clin Pharmacol. 1992 Jul;32(7):671–675. [PubMed]
- Chiriboga CA, Bateman DA, Brust JC, Hauser WA. Neurologic findings in neonates with intrauterine cocaine exposure. Pediatr Neurol. 1993 Mar–Apr;9(2):115–119. [PubMed]
- Chiriboga CA, Brust JC, Bateman D, Hauser WA. Dose-response effect of fetal cocaine exposure on newborn neurologic function. Pediatrics. 1999 Jan;103(1):79–85. [PubMed]
- Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einarson TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998 Sep 26;317(7162):839–843. [PMC free article] [PubMed]
- Dolovich Lisa R, Addis Antonio, Vaillancourt J M Régis, Power J D Barry, Koren Gideon, Einarson Thomas R. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998 Sep 26;317(7162):839–843. [PMC free article] [PubMed]
- Ursitti F, Klein J, Sellers E, Koren G. Use of hair analysis for confirmation of self-reported cocaine use in users with negative urine tests. J Toxicol Clin Toxicol. 2001;39(4):361–366. [PubMed]
- Delaney-Black V, Covington C, Ostrea E, Jr, Romero A, Baker D, Tagle MT, Nordstrom-Klee B, Silvestre MA, Angelilli ML, Hack C, Long J. Prenatal cocaine and neonatal outcome: evaluation of dose-response relationship. Pediatrics. 1996 Oct;98(4 Pt 1):735–740. [PubMed]
BMJ Group
Excretion of Δ9-tetrahydrocannabinol in sweat
- Marilyn A. Huestis
- Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
- Corresponding author. Fax: +1 410 550 2468.
Affiliations
, - Karl B. Scheidweiler
- Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
Affiliations
, - Takeshi Saito
- Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
- Tokai University School of Medicine, Kanagawa, Japan
Affiliations
, - Neil Fortner
- ChoicePoint, Inc., Alpharetta, GA
Affiliations
, - Tsadik Abraham
- Chemistry and Drug Metabolism, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
Affiliations
, - Richard A. Gustafson
- US Navy, Navy Drug Screening Laboratory, Jacksonville, FL, USA
Affiliations
, - Michael L. Smith
- Received 24 January 2007; received in revised form 27 March 2007; accepted 1 April 2007. published online 10 May 2007
Abstract
Sweat testing is a noninvasive technique for monitoring drug exposure over a 7-day period in treatment, criminal justice, and employment settings. We evaluated Δ9-tetrahydrocannabinol (THC) excretion in 11 daily cannabis users after cessation of drug use. PharmChek® sweat patches worn for 7 days were analyzed for THC by gas chromatography–mass spectrometry (GC/MS). The limit of quantification (LOQ) for the method was 0.4ng THC/patch. Sweat patches worn the first week of continuously monitored abstinence had THC above the United States Substance Abuse Mental Health Services Administration's proposed cutoff concentration for federal workplace testing of 1
ng THC/patch. Mean
±
S.E.M. THC concentrations were 3.85
±
0.86
ng THC/patch. Eight of 11 subjects had negative patches the second week and one produced THC positive patches for 4 weeks of monitored abstinence. We also tested daily and weekly sweat patches from seven subjects who were administered oral doses of up to 14.8
mg THC/day for five consecutive days. In this oral THC administration study, no daily or weekly patches had THC above the LOQ; concurrent plasma THC concentrations were all less than 6.1
μg/L. In conclusion, using proposed federal cutoff concentrations, most daily cannabis users will have a positive sweat patch in the first week after ceasing drug use and a negative patch after subsequent weeks, although patches may remain positive for 4 weeks or more. Oral ingestion of up to 14.8
mg THC daily does not produce a THC positive sweat patch test...read full article